MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart

References

• Gertz MA. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:503–510.
   PubMed Web of Science ®Google Scholar
• Buske C, Leblond V. How to manage Waldenstrom's macroglobulinemia. Leukemia 2013;27:762–772.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113:4163–4170.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012;367:826–833.
   PubMed Web of Science ®Google Scholar
• Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27:183–189.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013;121:2522–2528.
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121:2051–2058.
   PubMed Web of Science ®Google Scholar
• Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia 2013;27:1722–1728.
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504–4511.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp 194–195.
   Google Scholar
• Borowitz MJ, Bray R, Gascoyne R, et al. U.S.Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry 1997;30:236–244.
   PubMedGoogle Scholar
• Vince A, Poljak M, Seme K. DNA extraction from archival Giemsa-stained bone-marrow slides: comparison of six rapid methods. Br J Haematol 1998;101:349–351.
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160:171–176.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226–235.
   PubMedGoogle Scholar
• Janz S. Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol 2013;2013:815325.
   PubMedGoogle Scholar
• Yeole BB. Trends in the incidence of Non-Hodgkin's lymphoma in India. Asian Pac J Cancer Prev 2008;9:433–436.
   PubMed Web of Science ®Google Scholar
• Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013;54:1004–1011.
   PubMed Web of Science ®Google Scholar
• Yeole BB, Kurkure AP, Sunny L. Cancer survival in Mumbai (Bombay), India, 1992-1999. IARC Sci Publ 2011:133–42.
   Google Scholar
• Nimmagadda RBV, Digumarti R, Nair R, et al. Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: a multicenter registry based study from India. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol 2013;34:299–304.
   PubMedGoogle Scholar
• Kulkarni KP, Marwaha RK. Significant male preponderance in childhood acute lymphoblastic leukemia in India and regional variation: tertiary care center experience, systematic review, and evaluation of population-based data. Pediatr Hematol Oncol 2013;30:557–567.
   PubMed Web of Science ®Google Scholar
• Naresh KN, Agarwal B, Nathwani BN, et al. Use of the World Health Organization (WHO) classification of non-Hodgkin's lymphoma in Mumbai, India: a review of 200 consecutive cases by a panel of five expert hematopathologists. Leuk Lymphoma 2004;45:1569–1577.
   PubMed Web of Science ®Google Scholar
• Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications. Ann Oncol 2000;11(Suppl. 1):63–67.
   Google Scholar
• Sahni CS, Desai SB. Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma 2007;48:122–133.
   PubMed Web of Science ®Google Scholar
• Hodge LS, Ansell SM. Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease. Transfus Apher Sci 2013;49:19–23.
   PubMed Web of Science ®Google Scholar
• Aalipour A, Advani RH. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013;163:436–443.
   PubMed Web of Science ®Google Scholar
• Gunawardana C, Austen B, Powell JE, et al. South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to white patients. Br J Haematol 2008;142:606–609.
   PubMed Web of Science ®Google Scholar
• Nair CN, Chougule A, Dhond S, et al. Trisomy 12 in chronic lymphocytic leukemia--geographical variation. Leuk Res 1998;22: 313–317.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Naithani R, Mahapatra M, et al. Chronic lymphocytic leukemia in India--a clinico-hematological profile. Hematology 2007; 12:229–233.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Zibellini S, Arcaini L, et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 2013;122:2284–2285.
   PubMed Web of Science ®Google Scholar
• Paiva B, Montes MC, García-Sanz R, et al. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 2014;28: 166–173.
   PubMed Web of Science ®Google Scholar